Eli Lilly and Company (NYSE:LLY) Stake Raised by Park Capital Management LLC WI

Park Capital Management LLC WI raised its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 7.5% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 459 shares of the company’s stock after acquiring an additional 32 shares during the quarter. Park Capital Management LLC WI’s holdings in Eli Lilly and Company were worth $379,000 at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in the business. Brown Lisle Cummings Inc. boosted its holdings in shares of Eli Lilly and Company by 4.5% during the first quarter. Brown Lisle Cummings Inc. now owns 3,424 shares of the company’s stock worth $2,828,000 after purchasing an additional 146 shares during the period. HWG Holdings LP purchased a new position in shares of Eli Lilly and Company during the 1st quarter valued at $201,000. Palumbo Wealth Management LLC acquired a new position in shares of Eli Lilly and Company in the first quarter worth $411,000. M3 Advisory Group LLC raised its holdings in shares of Eli Lilly and Company by 8.2% during the first quarter. M3 Advisory Group LLC now owns 606 shares of the company’s stock worth $501,000 after acquiring an additional 46 shares in the last quarter. Finally, Live Oak Private Wealth LLC boosted its position in Eli Lilly and Company by 37.7% during the first quarter. Live Oak Private Wealth LLC now owns 2,705 shares of the company’s stock valued at $2,234,000 after purchasing an additional 741 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Trading Up 1.0%

Shares of NYSE:LLY opened at $770.16 on Tuesday. The company has a debt-to-equity ratio of 2.18, a quick ratio of 1.06 and a current ratio of 1.37. The stock’s 50-day moving average is $780.81 and its 200-day moving average is $800.36. The company has a market cap of $729.91 billion, a P/E ratio of 62.67, a P/E/G ratio of 1.11 and a beta of 0.41. Eli Lilly and Company has a 52-week low of $677.09 and a 52-week high of $972.53.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Thursday, May 1st. The company reported $3.34 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $4.64 by ($1.30). The business had revenue of $12.73 billion during the quarter, compared to analyst estimates of $12.77 billion. Eli Lilly and Company had a net margin of 22.67% and a return on equity of 85.51%. The business’s quarterly revenue was up 45.2% compared to the same quarter last year. During the same period last year, the business earned $2.58 EPS. Equities research analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, September 10th. Investors of record on Friday, August 15th will be given a dividend of $1.50 per share. This represents a $6.00 dividend on an annualized basis and a yield of 0.78%. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 48.82%.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on LLY shares. Morgan Stanley reaffirmed an “overweight” rating on shares of Eli Lilly and Company in a research report on Thursday, May 1st. Guggenheim reaffirmed a “buy” rating and set a $936.00 price objective on shares of Eli Lilly and Company in a research report on Friday. Hsbc Global Res downgraded shares of Eli Lilly and Company from a “strong-buy” rating to a “moderate sell” rating in a research report on Monday, April 28th. The Goldman Sachs Group upgraded shares of Eli Lilly and Company from a “neutral” rating to a “buy” rating and dropped their price target for the stock from $892.00 to $888.00 in a research note on Tuesday, April 8th. Finally, Erste Group Bank lowered shares of Eli Lilly and Company from a “buy” rating to a “hold” rating in a research note on Thursday, June 5th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and eighteen have assigned a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $1,011.79.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.